Feasibility, Acceptability and Fidelity of Integrating a Navigation Intervention Into Tobacco Treatment Program
NCT ID: NCT07072312
Last Updated: 2025-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
93 participants
INTERVENTIONAL
2022-11-10
2024-08-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient Navigation-based Tobacco Harm Reduction Program Among Cancer Patients
NCT04972916
Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care
NCT01678118
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
NCT00002520
Tobacco Use Treatment in Cancer Patients
NCT03482583
Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)
NCT02658032
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will employ a pre-post design with two cohorts (30 to the pre-intervention, and 90 to the intervention, respectively) to address the specific aims of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient Navigation
Participants receive patient navigation after their first and second tobacco treatment visits.
Adjuvant Patient Navigation for Tobacco Treatment
Patients in the study meet with the Patient Navigator two weeks after their first tobacco treatment visit and again after their second visit with the Tobacco Treatment Provider. The Patient Navigator will discuss psychosocial and other cessation barriers. The Patient Navigator will connect the patients with appropriate resources to help overcome these barriers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adjuvant Patient Navigation for Tobacco Treatment
Patients in the study meet with the Patient Navigator two weeks after their first tobacco treatment visit and again after their second visit with the Tobacco Treatment Provider. The Patient Navigator will discuss psychosocial and other cessation barriers. The Patient Navigator will connect the patients with appropriate resources to help overcome these barriers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. English speaking.
3. Age \> 18 years.
4. Active tobacco cigarette user, defined as having smoked a cigarette within the 30 days prior to enrollment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Temple University
OTHER
Fox Chase Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Linda Fleisher
Research Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda Fleisher, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
Temple Univeristy Health System - Fox Chase Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-1011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.